Drug intelligence / Profile preview

MRx0029

Development stage: Unknown
Lead developer: 4D pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MRx0029 is a live biotherapeutic product (LBP) consisting of a single strain of bacteria, Megasphaera massiliensis, which is naturally found in the healthy human gut. Developed by 4D pharma, it is an oral capsule formulation intended for the treatment of Parkinson's disease. Preclinical studies have shown that MRx0029 can reduce neuroinflammation, protect neurons from oxidative stress-induced death, improve gut barrier integrity, and promote the differentiation and survival of dopamine-producing neurons. The therapeutic rationale is based on modulating the gut-brain axis to address the underlying pathology of neurodegeneration. A Phase I clinical trial was planned to evaluate its safety and tolerability in patients with Parkinson's disease. However, the developer, 4D pharma, went into administration in June 2022, and its assets were later acquired by Armata Pharmaceuticals in March 2023, leaving the current development status of MRx0029 uncertain.

Other names: Megasphaera massiliensis

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on MRx0029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRx0029.

Explore the full profile